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Introduction: Dissemination of results of randomised controlled trials is traditionally limited to academic and
professional groups rather than clinical trial participants. While there is increasing consensus that results should
be communicated to trial participants, there is a lack of evidence on the most appropriate methods of dis-
semination. This study within a trial (SWAT) aims to address this gap by using a public and patient involvement
(PPI) approach to identify, develop and evaluate a patient-preferred method of receiving trial results of the
Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial (TRUST).
Methods: An experimental (intervention) study will be conducted using mixed methods to inform the devel-
opment of and evaluation of a patient-preferred method of communication of trial results. The study will involve
three consecutive phases. In the ﬁrst phase, focus groups of trial participants will be conducted to identify a
patient-preferred method of receiving trial results. The method will be developed and then assessed and reﬁned
by a patient and public expert group. In the second phase participants will be randomly assigned to the inter-
vention (patient-preferred method) and comparison groups (standard dissemination method as developed by the
lead study site in Glasgow, Scotland). In the third phase, a quantitative questionnaire will be used to measure
and compare patient understanding of trial results between the two groups.
Discussion: This protocol provides a template for other trialists who wish to enhance patient and public in-
volvement and additionally, will provide empirical evidence on how trialists should best disseminate study
results to their participants.
1. Background
Dissemination of trial results has traditionally been limited to three
channels: scientiﬁc meetings and peer reviewed publications and texts;
lay media; and groups and organizations with a particular health in-
terest [1]. However, the most recent iterative of the EU Clinical Trials
Regulation 536/2014 (Article 37) requires sponsors to provide sum-
mary results of clinical trials in a format understandable to laypersons
[2]. Therefore, disclosure of study results to trial participants is now a
mandatory fourth channel of dissemination. While it is desirable that
results are shared with study participants, there is a lack of evidence on
the most appropriate methods of sharing research ﬁndings with these
important stakeholders [1]. Since the ﬁndings exist in a context of
scientiﬁc exchange and debate, researchers need to ensure that the
information presented to participants meets their needs [1].
The move to disseminate trial results to trial participants had oc-
curred contemporaneously with the expanding role of Patient and
Public Involvement (PPI) in research. The Involve (UK) deﬁnition of PPI
is widely used and deﬁnes public involvement in research as research
being carried out ‘with’ or ‘by’ members of the public rather than ‘to’,
‘about’ or ‘for’ them [3]. The goal of PPI is to achieve a true partnership
between public/patients and researchers, leading to improved research
quality, relevance and outcomes. While PPI is gathering considerable
momentum internationally, limited attention has been placed on mea-
suring the impact of PPI [5,6]. Research in this area has often found to
be of poor quality and there have been diﬃculties in identifying the
exact contribution patient involvement has on overall patient care [7].
For these reasons a clear need has been established to measure the
impact of PPI in a valid, reliable and responsive way [5].
This study within a trial (SWAT) aims to address the lack of
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evidence on the most appropriate methods of sharing research ﬁndings
with trial participants by using a PPI approach to identify, develop and
evaluate a patient-preferred method of receiving trial results within the
Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial
(TRUST).
The TRUST clinical trial is a multi-centre, double blind, placebo
controlled, phase III clinical trial testing the eﬃcacy of thyroxine re-
placement in subclinical hypothyroidism in older community dwelling
adults. The study sites for the trial are the University of Glasgow,
Scotland (lead site); Leiden Academy on Vitality and Ageing, The
Netherlands; Leiden University Medical Centre, The Netherlands;
University of Berne, Switzerland; and University College Cork, Ireland.
This collaborative academic study recruited 738 participants with
subclinical hypothyroidism (SCH) over a three-and-a-half-year period
from 2013 to 2017 [4]. A total of 115 participants were recruited in
Ireland. The TRUST Trial completed recruitment in November 2016
and the results will be reported in Spring 2017.
2. Methods
Study Design: This study will adopt an experimental (intervention)
design using mixed methods to inform the development of and eva-
luation of a patient-preferred method of communication of trial results.
The design consists of three distinct phases (see Fig. 1).
Setting: The study will be conducted at the Irish TRUST site. The
hub centre for the Irish site was located at the Mercy University
Hospital, Cork with ﬁve satellite sites located at Waterford University
Hospital, Bantry General Hospital, Kerry General Hospital, St John's
Hospital Limerick and Vista Primary Care Centre, Naas. A total of 115
participants were recruited from these Irish sites and randomised to the
TRUST Trial.
Population: As this is a SWAT within the TRUST trial, the study
sample is determined by the trial. This study will consist of all TRUST
participants recruited in the Irish site (n = 115).
2.1. Phase one: qualitative data collection
Aim: To use a PPI approach to explore participants' perspectives and
preferences of result dissemination. This information will identify and
guide the development of the PPI informed result dissemination
method.
Design: Qualitative focus group study.
Method:
2.1.1. Focus groups
Three semi-structured focus groups will be conducted with four to
eight TRUST participants per focus group. Participants for this phase
will be determined based on the geographical feasibility of carrying out
the focus groups. Cork is the main site for TRUST in Ireland therefore all
Cork-based patients (n = 38) will be contacted via letter and invited to
participate in one of three focus groups in the Cork TRUST site. The
sessions will be led by an independent qualitative researcher. A topic
guide will be used to guide the focus groups. The Consensus-Oriented-
Decision-Making (CODM) model will be used in order to guide the
group to reach a consensus. The CODM model steps [8,9] include:
1 Framing the topic
2 Open discussion
3 Identifying underlying concerns
4 Collaborative proposal building
5 Choosing a direction
6 Synthesizing a ﬁnal proposal
7 Closure.
Analysis: Focus group recordings will be transcribed verbatim and
entered into NVivo Version 11 for thematic analysis. Braun and Clarke
[9] guidelines will be followed when thematic analysis is being per-
formed. Identiﬁed themes will be used to model a patient-preferred
method for the dissemination of results.
2.1.2. Patient and public expert group
A patient and public expert group will be established to assess the
content on and test the validity of the proposed trial result dissemina-
tion method. This group will consist of three to ﬁve TRUST participants
recruited from the Cork site. A series of consultations will take place
with this group in order to iteratively reﬁne the format of the patient-
preferred dissemination method.
Outcome: The ﬁndings from this phase will be used to identify and
develop the patient-preferred end-of-trial result dissemination method.
2.2. Phase two: intervention
Aim: To disseminate the results of the TRUST Trial to TRUST par-
ticipants.
Design: A prospective, randomised, single-blind, parallel-group in-
tervention group trial.
Method: Results will be disseminated to participants in Ireland after
the ﬁnal results of the trial are published in April 2017. Simple random
allocation will be used to randomise participants to the intervention or
Fig. 1. Study Design.
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comparison group. Participants from the patient and public expert
group (n = 3) will not be randomised as they will have already re-
viewed the content of the intervention method prior to randomisation.
The intervention group will receive the PPI informed dissemination
method and the comparison group will receive the standard dis-
semination method developed by the lead study site in Glasgow,
Scotland. Participants will be blinded to the result method they will
receive. One member of the research team will be un-blinded in order to
perform the randomisation and distribute the results of the trial.
Outcome: All TRUST participants will receive the results of the
TRUST Thyroid Trial.
2.3. Phase three: quantitative data collection
Aim: To measure the impact of PPI on patient understanding of end-
of-trial results.
Design: Quantitative questionnaire evaluation of the intervention.
Method: A questionnaire will be developed and validated to mea-
sure patient understanding of the end-of trial results. The questionnaire
will be developed in consultation with experts in the area of subclinical
hypothyroidism and scale development. It is expected that the ques-
tionnaire will contain no more than 10 items which will be measured on
a LIKERT scale. While there is debate in the literature regarding the
minimum required sample size for exploratory factor analysis, it has
been established that a ratio of 10 participants per variable is appro-
priate to produce solutions that are accurate representations of the
population parameters [10]. Questionnaire items will be developed by
adapting existing questionnaires and new items will be generated
where necessary through consultation with the content and scale de-
velopment experts and the patient and public expert group. Prior to
administering the full questionnaire, it will be reviewed by the patient
and public expert group to assess content and face validity. Any sug-
gestions and changes made by this group will be incorporated into the
ﬁnal questionnaire. The questionnaire will be sent to the intervention
and comparison groups one week after they have received the results of
the trial.
Analysis: Completed questionnaires will be entered into SPSS
software. The psychometric properties and construct validity of the
questionnaire will be examined with exploratory factor analysis, using
principal component analysis (PCA). PCA is a useful exploratory factor
analytic tool that can be incorporated into the development and re-
ﬁnement of new scales [11]. In this case, PCA will allow for the max-
imum amount of variance in patient understanding to be explained by
the smallest number of constructs. Internal consistency of the ques-
tionnaire will be investigated using Cronbach's alpha coeﬃcient. Where
possible, participant responses will be analysed using descriptive and
inferential (Chi-square test) statistics. The researcher carrying out the
input and analysis of this data will be blinded to the participants' al-
location status. Subgroup analysis will also be conducted to measure
how patient understanding is impacted by age, gender, education status
and study site attended.
Outcome: The primary outcome will be diﬀerence in levels of pa-
tient understanding between the intervention and comparison groups.
This will measure the impact of PPI on patient understanding of end of
trial results.
3. Discussion
The importance of engaging patients in the design and conduct of
clinical trials is increasingly recognised [1]. This protocol sets out a
rigorous approach to engaging patients in decisions about how best to
communicate trial results with trial participants. It will provide a useful
template for other clinical trialists who wish to enhance patient and
public involvement and additionally, will provide empirical evidence
on how trialists should best disseminate study results to their partici-
pants.
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